title: Type-1 cannabinoid receptor activity during Alzheimer's disease progression.
abstract: The activity of CB1 cannabinoid receptors was studied in postmortem brain samples of Alzheimer's disease (AD) patients during clinical deterioration. CB1 activity was higher at earlier AD stages in limited hippocampal areas and internal layers of frontal cortex, but a decrease was observed at the advanced stages. The pattern of modification appears to indicate initial hyperactivity of the endocannabinoid system in brain areas that lack classical histopathological markers at earlier stages of AD, indicating an attempt to compensate for the initial synaptic impairment, which is then surpassed by disease progression. These results suggest that initial CB1 stimulation might have therapeutic relevance.
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Spain.
authors.forename: Iván
authors.initials: I
authors.lastname: Manuel
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Spain.
authors.forename: Estíbaliz
authors.initials: E
authors.lastname: González de San Román
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Spain.
authors.forename: M Teresa
authors.initials: MT
authors.lastname: Giralt
authors.affiliation: Institut Neuropatologia, Servei Anatomia Patologica, Hospital Universitari de Bellvitge, Universitat de Barcelona, Hospitalet de Llobregat, CIBERNED, Spain.
authors.forename: Isidro
authors.initials: I
authors.lastname: Ferrer
authors.affiliation: Department of Pharmacology, Faculty of Medicine and Odontology, University of the Basque Country, Leioa, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Rodríguez-Puertas
mesh_terms: D000544:Alzheimer Disease / Q000473:pathology*; D000700:Analgesics / Q000494:pharmacology; D048588:Benzoxazines / Q000494:pharmacology; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D003511:Cyclohexanols / Q000493:pharmacokinetics; D003933:Diagnosis; D018450:Disease Progression; D005260:Female; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D006801:Humans; D007554:Isotopes / Q000493:pharmacokinetics; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D011877:Radionuclide Imaging; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects / Q000378:metabolism*; D018709:Statistics, Nonparametric
chemical_list: D000700:Analgesics; D048588:Benzoxazines; D003511:Cyclohexanols; D007554:Isotopes; D009025:Morpholines; D009281:Naphthalenes; D043884:Receptor, Cannabinoid, CB1; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
keywords: Alzheimer's disease; G-protein; cannabinoid receptors; functional autoradiography; ligand binding